抗糖尿病小分子ABHD6抑制剂的研究进展
发布时间：2018-07-17 21:34
【摘要】：2型糖尿病表现为糖脂代谢紊乱并伴随多脏器慢性损害,已成为威胁人类健康的巨大隐患。α/β水解酶结构域-6(α/βhydrolase domain-6,ABHD6)通过水解单酰甘油,负调控胰岛素的释放。小分子ABHD6抑制剂因其在增强胰岛素敏感性、改善脂肪功能等方面的重要作用而有望成为新一代治疗2型糖尿病的药物。本文介绍了ABHD6的作用机制,根据其结构特点对此类抑制剂的最新研究进展进行综述,并对其构效关系进行分析。
[Abstract]:Type 2 diabetes mellitus (T2DM) is characterized by disorder of glucose and lipid metabolism and chronic damage of multiple organs. 伪 / 尾 hydrolase domain 6 (伪 / 尾 hydrolase domain-6 ABHD6) negatively regulates the release of insulin by hydrolyzing monoacylglycerol. Small molecule ABHD6 inhibitors are expected to be a new generation of drugs for type 2 diabetes because of their important roles in enhancing insulin sensitivity and improving fat function. In this paper, the mechanism of ABHD6 is introduced, the latest research progress of ABHD6 is reviewed according to its structural characteristics, and its structure-activity relationship is analyzed.
【作者单位】： 中国药科大学新药研究中心;
【分类号】：R977.15
，
本文编号：2131004
[Abstract]:Type 2 diabetes mellitus (T2DM) is characterized by disorder of glucose and lipid metabolism and chronic damage of multiple organs. 伪 / 尾 hydrolase domain 6 (伪 / 尾 hydrolase domain-6 ABHD6) negatively regulates the release of insulin by hydrolyzing monoacylglycerol. Small molecule ABHD6 inhibitors are expected to be a new generation of drugs for type 2 diabetes because of their important roles in enhancing insulin sensitivity and improving fat function. In this paper, the mechanism of ABHD6 is introduced, the latest research progress of ABHD6 is reviewed according to its structural characteristics, and its structure-activity relationship is analyzed.
【作者单位】： 中国药科大学新药研究中心;
【分类号】：R977.15
，
本文编号：2131004
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2131004.html
最近更新
教材专著
